OCUPRESS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUPRESS (OCUPRESS).
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
| Metabolism | Primarily metabolized by aldehyde reductase and aldehyde dehydrogenase; minimal hepatic metabolism. |
| Excretion | Primarily renal elimination (≈80% unchanged); minor biliary excretion (≈20%). |
| Half-life | Terminal half-life ≈15 hours; in patients with renal impairment (CrCl <30 mL/min), half-life prolonged up to 30 hours. |
| Protein binding | ≈50% bound to albumin; negligible binding to α₁-acid glycoprotein. |
| Volume of Distribution | 0.15–0.25 L/kg; suggests limited tissue distribution (predominantly extracellular). |
| Bioavailability | Ocular: ≤30% via conjunctival and nasal absorption; systemic bioavailability negligible due to presystemic metabolism. |
| Onset of Action | Ocular administration: within 1–2 hours for intraocular pressure reduction; maximal effect at 4–6 hours. |
| Duration of Action | Effect duration ≥24 hours, permitting once-daily dosing; sustained reduction in intraocular pressure with regular use. |
1 drop of 0.25% or 0.5% ophthalmic solution in affected eye(s) twice daily (every 12 hours).
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for ophthalmic use; systemic absorption minimal. For severe renal impairment (CrCl <15 mL/min), use with caution due to potential accumulation of beta-blocker metabolites. |
| Liver impairment | No specific adjustments for ophthalmic use. In Child-Pugh class C cirrhosis, use with caution due to increased systemic exposure; consider monitoring for adverse effects. |
| Pediatric use | Safety and efficacy not established in pediatric patients. Use only if benefit justifies risk; dosing per adult guidelines with careful monitoring. |
| Geriatric use | Start with lowest available concentration (0.25%) once daily in elderly; titrate to response. Monitor for systemic effects (bradycardia, hypotension) due to potential age-related pharmacokinetic changes. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCUPRESS (OCUPRESS).
| Breastfeeding | Minimal systemic absorption suggests negligible excretion into breast milk. M/P ratio not determined. Caution advised due to lack of data; use only if clearly needed. |
| Teratogenic Risk | Ocufilcon A (OCUPRESS) is not systemically absorbed to significant levels from ocular application. No teratogenic effects have been reported in animal studies with topical ocular administration. However, as a general precaution, use during pregnancy only if clearly needed. No known fetal risk based on limited human data. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to apraclonidine or any component of the formulation","Use with monoamine oxidase inhibitors","Use in patients receiving systemic clonidine therapy"]
| Precautions | ["May cause allergic-like reactions (follicular conjunctivitis, lid edema, pruritus)","Use with caution in patients with severe cardiovascular disease, depression, or Raynaud's phenomenon","Monitor for ocular reactions; may require discontinuation"] |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required due to low systemic absorption. Standard prenatal care is recommended. |
| Fertility Effects | No known effects on fertility based on available animal and human data with topical ocular use. |